Bahram Valamehr - 13 Dec 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief R&D Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
13 Dec 2021
Net transactions value
-$1,123,156
Form type
4
Filing time
14 Dec 2021, 15:18:00 UTC
Previous filing
22 Nov 2021
Next filing
12 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $68,250 +25,000 +16% $2.73 181,698 13 Dec 2021 Direct F1
transaction FATE Common Stock Sale $95,928 -2,100 -1.2% $45.68* 179,598 13 Dec 2021 Direct F1, F2
transaction FATE Common Stock Sale $327,881 -7,018 -3.9% $46.72* 172,580 13 Dec 2021 Direct F1, F3
transaction FATE Common Stock Sale $312,512 -6,564 -3.8% $47.61* 166,016 13 Dec 2021 Direct F1, F4
transaction FATE Common Stock Sale $376,252 -7,718 -4.6% $48.75* 158,298 13 Dec 2021 Direct F1, F5
transaction FATE Common Stock Sale $78,832 -1,600 -1% $49.27* 156,698 13 Dec 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 +25,000 +69% $0.000000 61,156 13 Dec 2021 Common Stock 25,000 $2.73 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold from $45.18 to $46.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.
F3 Represents the weighted average sale price of the shares sold from $46.20 to $47.17 per share.
F4 Represents the weighted average sale price of the shares sold from $47.21 to $48.20 per share.
F5 Represents the weighted average sale price of the shares sold from $48.21 to $49.20 per share.
F6 Represents the weighted average sale price of the shares sold from $49.21 to $49.40 per share.
F7 This option is fully vested.